The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases

Trends in Cell Biology

Volumn 14, Issue 12, 2004, Pages 703-711

  Ross, Christopher A ^a   Pickart, Cecile M ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; PROTEASOME; UBIQUITIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BETA SHEET; CELL INCLUSION; DEGENERATIVE DISEASE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; MEDICAL INFORMATION; MOLECULAR BIOLOGY; NEUROTOXICITY; OLIGOMERIZATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 3142604036     PISSN: 09628924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcb.2004.10.006     Document Type: Review

References (93)

1. C.M. Pickart, and R.E. Cohen Proteasomes and their kin: proteases in the machine age Nat. Rev. Mol. Cell Biol. 5 2004 177 187
2. A.M. Weissman Themes and variations on ubiquitylation Nat. Rev. Mol. Cell Biol. 2 2001 169 178
3. D.M. Cyr Protein quality control: U-box-containing E3 ubiquitin ligases join the fold Trends Biochem. Sci. 27 2002 368 375
4. S. Wickner Posttranslational quality control: folding, refolding, and degrading proteins Science 286 1999 1888 1893
5. Y. Yang, and X. Yu Regulation of apoptosis: the ubiquitous way FASEB J. 17 2003 790 799
6. J. Adams Proteasome inhibitors as new anticancer drugs Curr. Opin. Oncol. 14 2002 628 634
7. L.T. Vassilev In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303 2004 844 848
8. D.C. Schwartz, and M. Hochstrasser A superfamily of protein tags: ubiquitin, SUMO and related modifiers Trends Biochem. Sci. 28 2003 321 328
9. P.R. Johnson Degradation signal masking by heterodimerization of MATalpha2 and MATa1 blocks their mutual destruction by the ubiquitin-proteasome pathway Cell 94 1998 217 227
10. C.W. Liu Endoproteolytic activity of the proteasome Science 299 2003 408 411
11. G.K. Tofaris Alpha-synuclein metabolism and aggregation is linked to ubiquitin- independent degradation by the proteasome FEBS Lett. 509 2001 22 26
12. C.A. Ross, and M.A. Poirier Protein aggregation and neurodegenerative disease Nat. Med. 10 2004 S10 S17
13. S.J. Berke, and H.L. Paulson Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration Curr. Opin. Genet. Dev. 13 2003 253 261
14. J.L. Price, and J.C. Morris Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease Ann. Neurol. 45 1999 358 368
15. C.J. Cummings Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice Neuron 24 1999 879 892
16. H. Shimura CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival J. Biol. Chem. 279 2004 4869 4876
17. L. Petrucelli CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation Hum. Mol. Genet. 13 2004 703 714
18. R.R. Kopito Aggresomes, inclusion bodies and protein aggregation Trends Cell Biol. 10 2000 524 530
19. P.J. Muchowski Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment Proc. Natl. Acad. Sci. U. S. A. 99 2002 727 732
20. Y. Gong Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss Proc. Natl. Acad. Sci. U. S. A. 100 2003 10417 10422
21. D.M. Walsh Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition Biochem. Soc. Trans. 30 2002 552 557
22. K.A. Conway Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct Science 294 2001 1346 1349
23. M.J. Volles, and P.T. Lansbury Jr Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease Biochemistry 42 2003 7871 7878
24. M.A. Poirier Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization J. Biol. Chem. 277 2002 41032 41037
25. I. Sanchez Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders Nature 421 2003 373 379
26. N.F. Bence Impairment of the ubiquitin-proteasome system by protein aggregation Science 292 2001 1552 1555
27. P. Venkatraman Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins Mol. Cell 14 2004 95 104
28. A. Michalik, and C. Van Broeckhoven The proteasome degrades soluble expanded polyglutamine completely and efficiently Neurobiol. Dis. 16 2004 202 211
29. L.G. Verhoef Aggregate formation inhibits proteasomal degradation of polyglutamine proteins Hum. Mol. Genet. 11 2002 2689 2700
30. Y. Tanaka Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis Hum. Mol. Genet. 10 2001 919 926
31. K.S. McNaught Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease Ann. Neurol. 56 2004 149 162
32. S. Chen Amyloid-like features of polyglutamine aggregates and their assembly kinetics Biochemistry 41 2002 7391 7399
33. S. Chen Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity J. Mol. Biol. 311 2001 173 182
34. C.A. Ross Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? Neuron 19 1997 1147 1150
35. C. Ross Polyglutamine pathogenesis. Emergence of unifying mechanisms for Huntington's disease and related disorders Neuron 35 2002 819 822
36. K.L. Sugars Decreased CRE-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis J. Biol. Chem. 279 2003 4988 4999
37. A. Kazantsev Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells Proc. Natl. Acad. Sci. U. S. A. 96 1999 11404 11409
38. J.S. Steffan The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription Proc. Natl. Acad. Sci. U. S. A. 97 2000 6763 6768
39. A. McCampbell CREB-binding protein sequestration by expanded polyglutamine Hum. Mol. Genet. 9 2000 2197 2202
40. F.C. Nucifora Jr Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity Science 291 2001 2423 2428
41. G. Schaffar Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation Mol. Cell 15 2004 95 105
42. H. Jiang Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein Hum. Mol. Genet. 12 2003 1 12
43. L. Stefanis Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death J. Neurosci. 21 2001 9549 9560
44. D.E. Dimcheff Prion proteins meet protein quality control Trends Cell Biol. 13 2003 337 340
45. J. Ma, and S. Lindquist Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation Proc. Natl. Acad. Sci. U. S. A. 98 2001 14955 14960
46. M. Hasegawa Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions J. Biol. Chem. 277 2002 49071 49076
47. M.S. Goldberg Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons J. Biol. Chem. 278 2003 43628 43635
48. A.B. Singleton alpha-Synuclein locus triplication causes Parkinson's disease Science 302 2003 841
49. M. Ghee Rat alpha-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex J. Neurochem. 75 2000 2221 2224
50. Y.A. Lam A proteasomal ATPase subunit recognizes the polyubiquitin degradation signal Nature 416 2002 763 767
51. H. Shimura Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease Science 293 2001 263 269
52. Y. Zhang Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1 Proc. Natl. Acad. Sci. U. S. A. 97 2000 13354 13359
53. B.I. Giasson, and V.M. Lee Parkin and the molecular pathways of Parkinson's disease Neuron 31 2001 885 888
54. L. Petrucelli Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons Neuron 36 2002 1007 1019
55. K.K. Chung S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function Science 304 2004 1328 1331
56. W. Kim, and W.G. Kaelin Jr The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer Curr. Opin. Genet. Dev. 13 2003 55 60
57. K.K. Chung Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease Nat. Med. 7 2001 1144 1150
58. K. Wakabayashi Synphilin-1 is present in Lewy bodies in Parkinson's disease Ann. Neurol. 47 2000 521 523
59. M. Tanaka Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease Nat. Med. 10 2004 148 154
60. E. Liani Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease Proc. Natl. Acad. Sci. U. S. A. 101 2004 5500 5505
61. Y. Imai CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity Mol. Cell 10 2002 55 67
62. Y. Imai An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin Cell 105 2001 891 902
63. Y.C. Tsai Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function J. Biol. Chem. 278 2003 22044 22055
64. J.J. Palacino Mitochondrial dysfunction and oxidative damage in parkin-deficient mice J. Biol. Chem. 279 2004 18614 18622
65. F. Darios Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death Hum. Mol. Genet. 12 2003 517 526
66. Y. Liu The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility Cell 111 2002 209 218
67. D.W. Miller L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system J. Biol. Chem. 278 2003 36588 36595
68. D.J. Moore Role for the ubiquitin-proteasome system in Parkinson's disease and other neurodegenerative brain amyloidoses Neuromolecular Med. 4 2003 95 108
69. O. Pornillos Mechanisms of enveloped RNA virus budding Trends Cell Biol. 12 2002 569 579
70. S. Willingham Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein Science 302 2003 1769 1772
71. J.S. Steffan Modification of huntingtin and Huntington's disease pathology Science 304 2004 100 104
72. H. Ueda Enhanced SUMOylation in polyglutamine diseases Biochem. Biophys. Res. Commun. 293 2002 307 313
73. S.W. Davies Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation Cell 90 1997 537 548
74. S. Waelter Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation Mol. Biol. Cell 12 2001 1393 1407
75. Y. Chai Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways J. Biol. Chem. 279 2004 3605 3611
76. J. Wang Copper-binding-site-null SOD1 causes ALS in transgenic mice: aggregates of non-native SOD1 delineate a common feature Hum. Mol. Genet. 12 2003 2753 2764
77. M. Farrer Lewy bodies and parkinsonism in families with parkin mutations Ann. Neurol. 50 2001 293 300
78. K.F. Winklhofer Geldanamycin restores a defective heat shock response in vivo J. Biol. Chem. 276 2001 45160 45167
79. P.W. Piper The Hsp90 chaperone as a promising drug target Curr. Opin. Investig. Drugs 2 2001 1606 1610
80. J.N. Buxbaum Diseases of protein conformation: what do in vitro experiments tell us about in vivo diseases? Trends Biochem. Sci. 28 2003 585 592
81. Y. Nagai Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening J. Biol. Chem. 275 2000 10437 10442
82. Y. Nagai Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila Hum. Mol. Genet. 12 2003 1253 1259
83. M.A. Findeis Peptide inhibitors of beta amyloid aggregation Curr. Top. Med. Chem. 2 2002 417 423
84. J.M. Lecerf Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease Proc. Natl. Acad. Sci. U. S. A. 98 2001 4764 4769
85. J. Legleiter Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy J. Mol. Biol. 335 2004 997 1006
86. A.R. Sawkar Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease Proc. Natl. Acad. Sci. U. S. A. 99 2002 15428 15433
87. S. Diamant Chemical chaperones regulate molecular chaperones in vitro and in cells under combined salt and heat stresses J. Biol. Chem. 276 2001 39586 39591
88. M. Tanaka Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective J. Biol. Chem. 279 2004 4625 4631
89. K.M. Sakamoto Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation Mol. Cell. Proteomics 2 2003 1350 1358
90. P. Talaga Beta-amyloid aggregation inhibitors for the treatment of Alzheimer's disease: dream or reality? Mini Rev. Med. Chem. 1 2001 175 186
91. S.J. Wood Selective inhibition of Abeta fibril formation J. Biol. Chem. 271 1996 4086 4092
92. N. Reixach Inhibition of beta-amyloid-induced neurotoxicity by imidazopyridoindoles derived from a synthetic combinatorial library J. Struct. Biol. 130 2000 247 258
93. V. Heiser Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay Proc. Natl. Acad. Sci. U. S. A. 99 2002 16400 16406